Ikarian Capital’s Akero Therapeutics AKRO Stock Holding History

Ikarian Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-206,854	Closed	-$9.82M	–	176
2025 Q3	$9.82M	Sell	206,854 -13,146	-6%	-$637K	0.99%	28
2025 Q2	$11.7M	Sell	220,000 -25,000	-10%	-$1.14M	2.25%	12
2025 Q1	$9.92M	Buy	+245,000	New	+$10.4M	1.22%	12
2023 Q4	–	Sell	-200,000	Closed	-$10.1M	–	140
2023 Q3	$10.1M	Buy	+200,000	New	+$9.31M	1.22%	22
2023 Q2	–	Sell	-50,000	Closed	-$1.91M	–	126
2023 Q1	$1.91M	Buy	+50,000	New	+$2.23M	0.43%	59

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ikarian Capital's AKRO Position: Q4 2025 in Review

Ikarian Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 206,854 shares — an estimated $9.82M sold.

Ikarian Capital first reported a position in AKRO in Q1 2023 and held it in 5 quarters. The position peaked at $11.7M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Ikarian Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 206,854 Akero Therapeutics shares in Q4 2025, an estimated $9.82M.
Ikarian Capital first reported a position in Akero Therapeutics in Q1 2023 and held it in 5 quarters.
Ikarian Capital's Akero Therapeutics position peaked at $11.7M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.